Pegvaliase

• CAT Number: I048025
• CAS Number: 1585984-95-7
• Molecular Formula: C15H30N2O5
• Molecular Weight: 318.4
• Purity: 98%
• Synonyms: Pegvaliase; rAvPAL-PEG; PEG-PAL; UNII-N6UAH27EUV; Pegvaliase [INN]
• Target: PAH
• Target Protein: P00439
• Appearance: Solid
• IUPAC Name: (2S)-2-amino-6-[6-(2-methoxyethoxy)hexanoylamino]hexanoic acid
• InChI: InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1
• InChIKey: NPOCDVAOUKODSQ-ZDUSSCGKSA-N
• SMILES: COCCOCCCCCC(=O)NCCCCC(C(=O)O)N

Pegvaliase is an enzyme replacement therapy used to treat phenylketonuria (PKU), a genetic disorder that affects the body’s ability to metabolize phenylalanine, an amino acid found in many foods. People with PKU have a buildup of phenylalanine, which can lead to intellectual disability, seizures, and other serious health problems. Pegvaliase works by breaking down phenylalanine into harmless byproducts, reducing the levels of phenylalanine in the body. It is administered as a subcutaneous injection and is typically used in combination with a phenylalanine-restricted diet to manage PKU. Pegvaliase has been shown to effectively lower phenylalanine levels in clinical trials.